The partners will provide the proprietary equipment that will serve as the technological core of the Polylactic Acid (PLA) production facility. This follows a licensing agreement signed in December 2024, reinforcing the strategic partnership between the two companies.
This milestone confirms Emirates Biotech’s transition from early planning to active project execution. Sulzer will manufacture and supply the essential proprietary equipment for the integrated PLA production process from lactic acid, which includes lactide formation, purification and polymerization technology.
Sulzer will deliver a full suite of proprietary equipment designed to maximise output, minimise energy use and support Emirates Biotech’s goal of providing renewable, recyclable and biodegradable plastics at industrial scale.
Tim Schulten, division president at Sulzer Chemtech, added: “Sulzer’s proven PLA technology was selected to enable reliable, efficient production while contributing to global efforts to decarbonize material supply chains. This project represents the kind of bold, solutions-driven investment that can make a real difference.”
Marc Verbruggen, CEO of Emirates Biotech, commented: “Signing this equipment supply contract with Sulzer represents a decisive step forward for Emirates Biotech. With proprietary equipment now secured, we are firmly entering the execution phase. This is a major commitment – not just financially, but strategically – as we lay the foundation for a state-of-the-art PLA facility that will anchor the region’s transition to sustainable materials.”
Samsung E&A will serve as the contractor for the PLA facility, integrating Sulzer’s proprietary equipment within the wider plant infrastructure, including utilities, storage facilities and other site services.
Construction is expected to commence in Q4 2025, with the plant operational by early 2028.